Proton Pump Inhibitors and Diarrhea

Adverse Effect Profile

Headaches, diarrhea, constipation, and nausea occur in up to 14% of older children and adults prescribed PPIs, according to the American Academy of Pediatrics 1
The most common side effects of PPIs include headache, diarrhea, constipation, and abdominal pain, as reported by the American Gastroenterological Association 2
If diarrhea occurs as a direct PPI side effect, switching to an alternative PPI or reducing the dose can usually circumvent these symptoms, as suggested by the American Gastroenterological Association 2

PPIs are listed among drugs that can cause diarrhea in advanced care patients not receiving oncological therapies, according to the European Society for Medical Oncology 3
Diarrhea is a recognized side effect of many drug classes including proton pump inhibitors, and all laxatives must be stopped when diarrhea occurs with enteral tube feeding, as recommended by the European Society of Gastrointestinal Endoscopy 4
Antibiotics combined with PPIs have higher incidence of diarrhea than antibiotics alone, likely due to altered intestinal flora, as reported by the European Society of Gastrointestinal Endoscopy 4

Review all concurrent medications and stop all laxatives, check for magnesium-containing antacids, sorbitol-containing drugs, and other diarrhea-inducing medications, as recommended by the European Society of Gastrointestinal Endoscopy 4
Trial PPI discontinuation or dose reduction if no definitive indication for chronic PPI exists, attempt de-prescribing or step down from twice-daily to once-daily dosing, as suggested by the American Gastroenterological Association 5
Switch to alternative PPI or H2-receptor antagonist if PPI is necessary but diarrhea persists, try a different PPI or consider switching to an H2RA, as recommended by the American Gastroenterological Association 2

C. difficile toxin is found in 20-50% of patients with antibiotic-related diarrhea on enteral tube feeding, as reported by the European Society of Gastrointestinal Endoscopy 4
Long-term use of PPIs or post-surgical loss of the ileocecal valve can lead to SIBO, according to the European Society for Medical Oncology 6

Patients discontinuing long-term PPI therapy may develop transient upper GI symptoms due to rebound acid hypersecretion, a physiologic phenomenon where the stomach's increased parietal cell mass unleashes heightened acid production once PPIs are stopped, according to the American Gastroenterological Association 7

The American Gastroenterological Association recommends reviewing the original indication for PPI therapy and determining if ongoing treatment is justified, considering de-prescription or dose reduction to the lowest effective level 8, 9
Patients without high-risk features, such as history of upper GI bleeding or severe erosive esophagitis, can safely attempt PPI discontinuation, with warning about potential rebound symptoms lasting several weeks after discontinuation, as suggested by the American Gastroenterological Association 7
For patients with controlled symptoms and no erosive disease at baseline, the American Gastroenterological Association suggests weaning to on-demand therapy with H2 blockers or antacids, and implementing aggressive lifestyle modifications to reduce PPI dependence 8, 9
The American Gastroenterological Association recommends evaluating for other causes of digestive symptoms unrelated to PPI therapy, and considering cognitive behavioral therapy or gut-directed hypnotherapy for patients with functional overlay contributing to symptoms 8, 9

For severe disease requiring continued therapy, the American Gastroenterological Association suggests using the lowest effective dose that maintains symptom control, as part of optimizing PPI therapy when continuation is necessary 8, 9
Patients without erosive disease (Los Angeles grade B or higher) or Barrett's esophagus should consider discontinuation rather than managing side effects, according to the American Gastroenterological Association 10, 11

The American Gastroenterological Association notes that PPIs increase the risk of Clostridium difficile infection in hospitalized patients, though the risk is considered "slight" in magnitude 12, 13
The American Gastroenterological Association recommends using the lowest effective PPI dose that controls symptoms, to minimize disruption to the gut microbiome 13, 14

The American Gastroenterological Association suggests limiting treatment duration to the minimum necessary for the clinical indication, with a 10-week course being appropriate for certain conditions but not exceeding necessary durations 13, 14
Discontinuing PPI therapy after the prescribed course and initiating probiotic supplementation can help restore the gut microbiome, as recommended by Clinical Gastroenterology and Hepatology guidelines 15

Lifestyle modifications, including dietary changes, head-of-bed elevation, and avoiding meals within 3 hours of bedtime, can help manage symptoms without medication, as suggested by Clinical Gastroenterology and Hepatology 15